Telemedicine to Enhance Adherence to CPAP Therapy in Patients With OSAS
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We hypothesize that the use of telemedicine combined with support interventions by short messages, telephone calls and ambulatory visits to control CPAP treatment during the first month improves adherence and reduces unresolved side effects of therapy.
The primary objective of an OSAS treatment program is to successfully implement indicated CPAP in the highest possible proportion of patients in order to lower the proportion of untreated OSAS in the population. On an individual basis, it has been shown that a longer duration of CPAP use is associated with better outcomes in terms of daytime functioning and in the control of metabolic and blood pressure effects of CPAP. For our study, we have therefore decided to use 2 co-primary endpoints, taking into account both aspects of adherence mentioned. Cardiovascular complications are a major concern in OSAS patients. Effective CPAP treatment has been shown to reduce surrogate measures of cardiovascular risk. We hypothesize that intensified efforts for CPAP adherence with telemedicine has a positive impact on a number of surrogate measures of the cardiovascular risk at 1 and 6 months of treatment.
| Condition | Intervention |
|---|---|
|
Obstructive Sleep Apnea Syndrome |
Device: Telemedicine intervention |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study |
- Proportion of nights with CPAP use (defined as ≥1h of CPAP use per night within the last month including nights of no-use of CPAP) at 6 months [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
- Average nightly use of CPAP during the first 6 months of treatment (minutes per night including nights of no-use of CPAP since day 1) [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
- Proportion of nights with efficient CPAP use (defined as ≥4h of CPAP use per night within the last month including nights of no-use of CPAP) at 6 months [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
- Average nightly use of CPAP during the first 6 months of treatment (minutes per night excluding nights of no-use of CPAP) [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
- Proportion of CPAP users (defined as ≥1h of CPAP use per night within the last week) at 1 month [ Time Frame: at 1 month ] [ Designated as safety issue: No ]
- Average nightly use of CPAP during the first month of treatment (minutes per night including nights of no-use of CPAP since day 1) [ Time Frame: at 1 month ] [ Designated as safety issue: No ]
- Proportion of efficient CPAP users (defined as ≥4h of CPAP use per night within the last week including nights of no-use of CPAP) at 1 month [ Time Frame: at 1 month ] [ Designated as safety issue: No ]
- Average nightly use of CPAP during the first month of treatment (minutes per night excluding nights of no-use of CPAP) [ Time Frame: at 1 month ] [ Designated as safety issue: No ]
- Mask leakage at 1 and 6 months [ Time Frame: at 1 and 6 months ] [ Designated as safety issue: No ]
- Adverse effects on CPAP at 1 and 6 months [ Time Frame: at 1 and 6 months ] [ Designated as safety issue: No ]The proportion of patients with insomnia/dyssomnia due to CPAP, skin problems due to the mask, oronasal dryness or other treatment related complaints is assessed.
- Patient satisfaction (measured with a specifically designed short questionnaire and on a visual analogue scale (VAS)) at 1 and 6 months [ Time Frame: at 1 and 6 months ] [ Designated as safety issue: No ]
- Likelihood of discontinuing CPAP is estimated with Kaplan Meyer analysis and groups are compared with the Cox proportional hazard ratio analysis. [ Time Frame: at 6 months ] [ Designated as safety issue: No ]
- Cardiovascular risk factors in serum (e.g. cholesterol, C-peptid, ...), blood pressure and night time assessment of sleep quality with the novel assessment tool "SOMNOcheck micro". [ Time Frame: at 1 and 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 400 |
| Study Start Date: | December 2012 |
| Estimated Primary Completion Date: | September 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Telemedicine intervention
In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if
|
Device: Telemedicine intervention
Other Name: ResMed Telemedicine S9 Wireless-Modul
|
|
No Intervention: Control (without telemedicine)
In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptomatic OSAS patients with an AHI and an oxygen desaturation index (ODI) of >5/h in polysomnography (PSG) consenting to start longterm CPAP treatment.
Exclusion Criteria:
- Age <18 years
- Unable to communicate in German, English, French or Italian
- Alcohol consumption > 4 units >4 times a week
- Acute manifestation of psychiatric diseases
- Life expectancy of < 6 months for any reason
- Surgical obesity treatment planned within the next 6 months
- Predominantly Central sleep apnea and cheyne stokes respiration
Contacts and Locations| Contact: Otto D Schoch, MD | 0041 71 494 2634 | otto.schoch@kssg.ch |
| Contact: Florent Baty, PhD | 0041 71 494 2809 | florent.baty@kssg.ch |
| Switzerland | |
| Cantonal Hospital St. Gallen | Not yet recruiting |
| St. Gallen, CH, Switzerland, 9007 | |
| Contact: Otto D Schoch, MD 0041 71 494 2634 otto.schoch@kssg.ch | |
| Principal Investigator: Otto D Schoch, MD | |
| Study Director: | Martin Brutsche, MD, PhD | Cantonal Hospital St. Gallen |
More Information
Publications:
| Responsible Party: | Otto D. Schoch, Sponsor investigator, Cantonal Hospital of St. Gallen |
| ClinicalTrials.gov Identifier: | NCT01715194 History of Changes |
| Other Study ID Numbers: | EKSG 12/076 |
| Study First Received: | October 10, 2012 |
| Last Updated: | October 24, 2012 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by Cantonal Hospital of St. Gallen:
|
OSAS CPAP Adherence Telemedicine |
Additional relevant MeSH terms:
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013